

RESTRICTED BENEFIT CRITERIA - TRELEGY

PROVINCE/PROGRAM	INDICATION	CRITERIA
Alberta ST/SA	COPD 100/62.5/25 mcg	COPD uncontrolled on dual therapy (LAMA/LABA or ICS/LABA)
British Columbia SA	COPD 100/62.5/25 mcg	Moderate to severe COPD exacerbating on dual therapy (LAMA/LABA or ICS/LABA)
Manitoba EDS	COPD 100/62.5/25 mcg	COPD uncontrolled on dual therapy
New Brunswick SA	COPD 100/62.5/25 mcg	COPD uncontrolled on LAMA/LABA
NIHB LU	COPD 100/62.5/25 mcg	COPD uncontrolled on dual therapy (ICS/LABA or LAMA/LABA or ICS/LAMA)
Newfoundland and Labrador SA	COPD 100/62.5/25 mcg	COPD uncontrolled on LAMA/LABA
Nova Scotia EDS	COPD 100/62.5/25 mcg	COPD uncontrolled on LAMA/LABA
Ontario LU Code	COPD 100/62.5/25 mcg	567 COPD requiring triple therapy (ICS + LAMA + LABA)
Quebec RAMQ Code	COPD 100/62.5/25 mcg	RE384 COPD exacerbating on LAMA/LABA or asthma component (ACO) or on ICS/LAMA/LABA
Prince Edward Island SA	COPD 100/62.5/25 mcg	COPD uncontrolled on LAMA/LABA
	ACO 100/62.5/25 mcg	In patients with asthma/COPD overlap
Saskatchewan EDS	COPD 100/62.5/25 mcg	COPD uncontrolled on dual therapy (LAMA/LABA or ICS/LABA) COPD on open triple therapy
Yukon EDS	COPD 100/62.5/25 mcg	Moderate to very severe COPD exacerbating on dual therapy (LAMA/LABA or ICS/LABA) for at least 6 months

COPD: chronic obstructive pulmonary disease, EDS: Exception Drug Status, ICS: inhaled corticosteroids, LABA: long-acting beta-agonist, LAMA: long-acting muscarinic antagonist, LU: limited use, NIHB: Non-insured health benefit, RAMQ: Régie de l'assurance maladie du Québec, SA: Special Authorization, ST: Step therapy